Home/ Stocks/ FDMT

4D Molecular Therapeutics, Inc. Common Stock

FDMT XNAS

$10.14 +0.21 (+2.11%) ▲ 15-min delayed

Open

$9.08

High

$10.15

Low

$9.06

Volume

832.1K

Market Cap

$530.08M

About 4D Molecular Therapeutics, Inc. Common Stock

4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 196 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$3.05M	$-68,760,000	$-1.01
FY 2025	$85.21M	$-140,109,000	$-2.42
Q3 2025	$90.0K	$-56,876,000	$-1.01
Q2 2025	$15.0K	$-54,658,000	$-0.98

Related Market News

No specific coverage for FDMT yet. Check out our latest market news or earnings calendar.

Get FDMT Alerts

Stay ahead with breaking news, price alerts, and expert analysis on 4D Molecular Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.